Navigation Links
Ascendis Pharma Announces the Appointment of Thomas P. Soloway as Chief Financial Officer

COPENHAGEN, Denmark, Jan. 9, 2014 /PRNewswire/ -- Ascendis Pharma A/S announced today that Thomas P. Soloway has been appointed Chief Financial Officer.  Mr. Soloway joins the company after holding the positions of Chief Financial Officer and Chief Operating Officer at Transcept Pharmaceuticals, Inc.

"Tom's strong background in both the US capital markets and operating positions will be an important asset to Ascendis," stated Jan Moller Mikkelsen, Chief Executive Officer.  "Tom will play a key leadership role as we continue to execute on our strategic plan.  Tom joins our organization at a particularly exciting time. In addition to our large pharma partnerships in diabetes, pulmonary arterial hypertension and ophthalmology, we recently initiated a Phase 2 trial with our human growth hormone product in children, and launched a new initiative in the large and growing osteoarthritis market."

Mr. Soloway said, "What attracts me to Ascendis is its experienced leadership team, a strong pipeline of development stage programs, and a clinically proven prodrug technology platform that has been commercially validated by large pharma partnerships.  I am excited to join a company with a track record of strong execution and look forward to contributing to our continued growth."

Mr. Soloway joins Ascendis from Transcept Pharmaceuticals, Inc. where he was a co-founder of the company and served initially as Chief Financial Officer and later as Executive Vice President and Chief Operating Officer.  In these roles, Mr. Soloway led all investor relations activities and was a key member of the executive management team overseeing clinical development, regulatory affairs, pharmaceutical sciences, manufacturing and all financial activities.  Mr. Soloway led Transcept through its transition from a private to public company and raised more than $200 million for Transcept during his tenure.  Earlier in his career, Mr. Soloway was a Principal at Montreux Equity Partners, a life sciences focused venture capital firm. Mr. Soloway received a Bachelor of Science in Entrepreneurial Studies from the University of Southern California and a Masters of Business Administration from Georgetown University.

About Ascendis Pharma

Ascendis Pharma develops differentiated prodrug versions of high-value drugs. The company's proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent life.

Ascendis Pharma has a diversified and balanced high-value pipeline. Ascendis has strategic partnerships with Sanofi in diabetes, United Therapeutics in pulmonary arterial hypertension and an undisclosed market leader in the field of ophthalmology.

For more information, visit  

Thomas P. Soloway
Chief Financial Officer, Ascendis Pharma A/S
Phone: 415.699.9924


SOURCE Ascendis Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
2. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
5. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
6. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
7. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
8. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
9. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
10. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
11. Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
Breaking Medicine News(10 mins):